 |
| Proton Pump Inhibitors Market |
The proton pump inhibitors market offers a range of medications that help reduce stomach acid production. Prescription proton pump inhibitors are effective in treating conditions where excess stomach acid is present, such as acid reflux, stomach ulcers, and heartburn. They provide quick and long-lasting relief from frequent acid reflux symptoms. The global rise in gastrointestinal issues like acidity, heartburn, and ulcers is driving significant demand for PPI drugs.
The Global Proton Pump Inhibitors Market
is estimated to be valued at US$ 3.8 Mn in 2024 and is expected to exhibit a
CAGR of 6.7% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the proton pump inhibitors are Horizon Therapeutics
plc, Ammonett Pharma LLC, Medison Pharma Ltd., Modern Dietetics Inc., Synageva
BioPharma Corp., Medison Pharma Ltd., Swedish Orphan Biovitrum AB (Sobi),
Entera Health, Inc., Dipharma Francis S.r.l., Ucyclyd Pharma, Inc. These
companies hold a majority market share and are focusing on developing
innovative drug formulations and delivery methods.
The growing population diagnosed with gastric issues like GERD and ulcers
present lucrative growth opportunities. Market players are investing in R&D
to expand the therapeutic applications of PPIs.
Globally, the prevalence of lifestyle diseases is increasing rapidly in
developing nations. Key companies are looking at these emerging markets for
expansion opportunities. Partnerships with local players help increase
geographical presence and access to new customer segments.
Market drivers – The rising geriatric population prone to gastrointestinal
disorders coupled with growing awareness about proton pump inhibitors drives
the market growth. Changing lifestyles leading to stress and unhealthy diets
have contributed to a spike in acid reflux diseases.
Market restraints – Patent expirations of popular PPI drug brands enable
generic competition, posing a challenge. Strict regulatory norms for new drug
approvals and adverse drug reactions associated with long-term PPI usage also
limit market potential. High treatment costs in some nations restrict
widespread adoption of PPI medications.
Segment Analysis
The Proton
Pump Inhibitors Market Demand is
dominated by the esomeprazole sub segment. Esomeprazole accounts for around 60%
of the total market owing to its superior efficacy in treating conditions like
gastroesophageal reflux disease and peptic ulcers. It has minimal adverse
effects compared to other proton pump inhibitors, making it a preferred choice
for both clinicians and patients. The pantoprazole sub segment follows
esomeprazole in terms of market share due to its effectiveness and longer
duration of action.
Global Analysis
The North American region accounts for over 40% of the global proton pump
inhibitors market. This is attributed to the high prevalence of acid reflux
disorders and availability of advanced healthcare facilities in countries like
the US and Canada. However, the Asia Pacific region is witnessing the fastest
growth and is projected to surpass North America in the coming years. Factors
such as rising affordability, growing awareness among public regarding acid
reflux management, and increasing healthcare expenditure are contributing to
the growth of the market in Asia Pacific countries like China, India and Japan.
Additionally, the presence of major generic manufacturers in India and China is
also augmenting the regional market growth.
0 Comments